Tilray Brands (TLRY)
(Delayed Data from NSDQ)
$1.63 USD
+0.04 (2.52%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.62 -0.01 (-0.61%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.63 USD
+0.04 (2.52%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.62 -0.01 (-0.61%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth C Momentum D VGM
Zacks News
Should You Buy the Coinbase IPO?
by Tracey Ryniec
Coinbase is the hottest IPO of the year but history shows it could be a wild ride.
Tilray, Inc. (TLRY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed the most recent trading day at $19.77, moving +0.05% from the previous trading session.
Do Options Traders Know Something About Tilray (TLRY) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.
Inside the Top-Performing ETFs of Q1
by Sweta Killa
Amplify Seymour Cannabis ETF (CNBS) topped the list of the best-performing ETFs of February with impressive returns of about 60%.
Tilray, Inc. (TLRY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed the most recent trading day at $22.04, moving +1.9% from the previous trading session.
Tilray, Inc. (TLRY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Tilray, Inc. (TLRY) closed at $27.47, marking a +1.85% move from the previous day.
Cannabis ETF (MSOS) On a High, Reaches $1B AUM Milestone
by Sweta Killa
AdvisorShares Pure US Cannabis ETF (MSOS) has been surging in popularity with its assets growing more than 40,000% in just six months.
Do Options Traders Know Something About Tilray (TLRY) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.
Markets Break Higher; NVIDIA Beats Q4 Expectations
by Mark Vickery
NVIDIA (NVDA) beat estimates on both top and bottom lines after regular trading this afternoon.
Should You Invest in Marijuana Stocks & ETFs Now?
by Neena Mishra
CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.
Dow Sets New High; Tilray & Twilio Beat
by Mark Vickery
Cannabis supply giant Tilray (TLRY) is up 14% in the late market, following a 9% sell-off in regular day trading.
Tilray, Inc. (TLRY) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tilray, Inc. (TLRY) delivered earnings and revenue surprises of 42.86% and 1.82%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fourth-quarter 2020 results.
Marijuana ETFs on a High on Reddit Frenzy
by Sanghamitra Saha
After promoting GameStop (GME) and Silver, Reddit's discussion has now popularized marijuana stocks like Sundial Growers (up 78.8% on Feb 10) and Tilray (up more than 50% on Feb 10).
Meridian Bioscience, CRISPR Therapeutics, Tilray and Uber highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Meridian Bioscience, CRISPR Therapeutics, Tilray and Uber highlighted as Zacks Bull and Bear of the Day
3 Stocks to Benefit From the Rapid Adoption of Marijuana
by Zacks Equity Research
The marijuana industry looks set to witness growth going forward due to wider adoption, making it prudent to look at names like Scotts Miracle-Gro (SMG), GrowGeneration (GRWG) and Tilray (TLRY)
Tilray Bought by the Reddit Crowd, Plus UBER's Q3
by Mark Vickery
Shares of the marijuana pharma company shot up another 51% Wednesday, following a +44% performance yesterday; Tilray is now up 400% in just the last month alone.
Cannabis Stocks Rise on Hopes of Federal Legalization in US
by Zacks Equity Research
Cannabis stocks seem poised to gain on hopes of removal of the federal ban on cannabis products under the new administration.
The Zacks Analyst Blog Highlights: Canopy Growth, Tilray, Cisco Systems, Twitter and Lyft
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Canopy Growth, Tilray, Cisco Systems, Twitter and Lyft
Pot Stocks Take Markets Higher; Plus Beats for Cisco, Twitter, Lyft
by Mark Vickery
With Tilray (TLRY) +44% and Canopy (CGC) +12% on the day, the Nasdaq and Russell 2000 managed to climb to fresh all-time highs Tuesday.
Cannabis ETFs Spike on Jazz-GW Pharma Deal
by Sweta Killa
Jazz Pharmaceuticals (JAZZ) agreed to buy cannabinoid drug company GW Pharmaceuticals (GWPH) for $7.2 billion in cash and stock that has strengthened the bullish case for the cannabis industry.
Cannabis ETF Tops in January: 5 Stocks That Led the Way
by Sweta Killa
Inside the top performing stocks in the top ETF of January.
Sunoco, Lemonade, Tilray, Innovative Industrial Properties and Square highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Sunoco, Lemonade, Tilray, Innovative Industrial Properties and Square highlighted as Zacks Bull and Bear of the Day
3 Marijuana Stocks to Play the Green Rush in 2021
by Tirthankar Chakraborty
Marijuana stocks are set to be the rage on Wall Street in hopes of legalization in and around the United States, which calls for keeping an eye on the likes of Tilray (TLRY) and Square (SQ).
Is Tilray (TLRY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (TLRY) Outperforming Other Medical Stocks This Year?